(Q37602286)

21 August 2017

1 reference

title

Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept (English)

1 reference

triple-negative breast cancer

21 August 2017

1 reference

1 reference

Sabine C Linn

1

1 reference

21 August 2017

Laura J Van 't Veer

series ordinal

2

1 reference

21 August 2017

language of work or name

1 reference

1 September 2009

1 reference

European Journal of Cancer

21 August 2017

published in

1 reference

21 August 2017

volume

45 Suppl 1

1 reference

21 August 2017

page(s)

11-26

1 reference

The global breast cancer burden: variations in epidemiology and survival.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Molecular profiling of breast cancer: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Triple-negative breast cancer: risk factors to potential targets

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Treating the genetic make-up of breast cancer: a new fashion?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Commentary: hormone receptor testing in breast cancer: a distress signal from Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Triple negative tumours: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Epidemiology of basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Differences in risk factors for breast cancer molecular subtypes in a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Basal-like breast cancer and the BRCA1 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

MYC is amplified in BRCA1-associated breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

DNA copy number alterations and expression of relevant genes in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The role of BRCA1 in transcriptional regulation and cell cycle control

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The role of BRCA1 in the cellular response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The XIST noncoding RNA functions independently of BRCA1 in X inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Further evidence for BRCA1 communication with the inactive X chromosome.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

X chromosomal abnormalities in basal-like human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

BRCA1 mutations in primary breast and ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

BRCA1 dysfunction in sporadic basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Id family of helix-loop-helix proteins in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The epidemiology of triple-negative breast cancer, including race

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Advances in breast cancer: pathways to personalized medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Sonographic correlations with the new molecular classification of invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Triple-negative breast cancer: correlation between MR imaging and pathologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

1 reference

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Targeting epidermal growth factor receptor--are we missing the mark?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Concordance among gene-expression-based predictors for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Neoadjuvant chemotherapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Research issues affecting preoperative systemic therapy for operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Triple-negative breast cancer: therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Tiling path genomic profiling of grade 3 invasive ductal breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Therapeutic strategies for triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Integrating genetic approaches into the discovery of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970012-7

7 January 2021

10.1016/S0959-8049(09)70012-7

Identifiers

DOI

1 reference

21 August 2017

1 reference